Pseudo-addiction in cancer patients and rapid-release fentanyl for breakthrough pain: An increasingly common concern

Med Clin (Barc). 2021 Sep 24;157(6):e287. doi: 10.1016/j.medcli.2020.07.024. Epub 2020 Aug 18.

[Article in English, Spanish]

Authors

Víctor Amezcua¹, Kevin Doello², Desirée González-Callejas³

Affiliations

¹ Medical Oncology Department, Virgen de las Nieves University Hospital, Granada, Spain. Electronic address: victor.amezcua.md@gmail.com.
² Medical Oncology Department, Virgen de las Nieves University Hospital, Granada, Spain.
³ Pharmacy Department, Virgen de las Nieves University Hospital, Granada, Spain; Opioids Prescription Program, Andalusian Government, Spain.

PMID: 32819770
DOI: 10.1016/j.medcli.2020.07.024

No abstract available

Publication types

Letter

MeSH terms

Analgesics, Opioid / adverse effects
Breakthrough Pain* / drug therapy
Breakthrough Pain* / etiology
Fentanyl
Humans
Neoplasms* / complications

Substances

Analgesics, Opioid
Fentanyl